Spravato Nasal Spray
Multi-Dose Nasal Delivery
Janssen selected an Aptar technology as the preferred drug delivery device for their Esketamine drug product, used to treat severe depression. The project team identified a need to improve usability of the core device and saw Shore as the perfect partner to lead this aspect of the program.
Showcasing the strengths of our combined design and engineering team, this project saw us successfully customise the platform drug delivery device to meet the needs of the user group and commercial launch objectives of our customer. Included in our scope was the development of a commercial IFU and secondary packaging to compliment the improved device design.
Our innovative solution enhances the usability of the device whilst ensuring no impact to the core functional elements of the platform technology.
- Platform device customised to customer and patient needs
- Improved reliability and performance in users hands
- Enhanced user interface
- Complimentary packaging and IFU solutions
- Valuable intellectual property generated for Janssen
Prototype & Evaluation
New Product Integration
Thank you for your critical contribution to this program. We could not have done this without you. Shore has done so much for the Esketamine program: all the design and engineering support starting way back in 2012, and the amazing commercial trainer. You are an integral part of the care, dedication, and teamwork that made this possible.
Engineering Director, Janssen R&D